AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4941924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent compression of the lower limb during surgery
Number of subjects: 39
Study 4941924 — intervention group
Group type: COMPARATOR
Intervention: Control (uncompressed legs)
Number of subjects: 39
Study 31848211 — intervention group
Group type: EXPERIMENTAL
Intervention: Core outcomes for age-related macular degeneration trials
Number of subjects: 301
Study 30269924 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular triamcinolone acetonide (PTA)
Number of subjects: 0
Study 30269924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (ITA)
Number of subjects: 0
Study 30269924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (IDI)
Number of subjects: 0
Study 28449205 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaborative care (pharmacist-involved)
Number of subjects: 411
Study 28449205 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 411
Study 26241433 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg per day
Number of subjects: 899
Study 26241433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral 17-beta-estradiol (E2) 0.5 mg per day
Number of subjects: 899
Study 26241433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose venlafaxine XR 75 mg per day
Number of subjects: 899
Study 26241433 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 899
Study 26241433 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic yoga
Number of subjects: 899
Study 26241433 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 fatty acid supplementation 1.8 g per day
Number of subjects: 899
Study 23727002 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-1018 (2 doses at 0 and 4 weeks)
Number of subjects: 0
Study 23727002 — intervention group
Group type: COMPARATOR
Intervention: HBsAg-Eng (3 doses at 0, 4, and 24 weeks)
Number of subjects: 0
Study 23727002 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-1018
Number of subjects: 0
Study 23727002 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-1018 and HBsAg-Eng
Number of subjects: 0
Study 21732272 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 34
Study 21732272 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 34
Study 19390535 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2720
Study 19390535 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 2720
Study 16495471 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 microg daily)
Number of subjects: 1004
Study 12938843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 100
Study 12825772 — intervention group
Group type: EXPERIMENTAL
Intervention: Animacy decision task
Number of subjects: 0
Study 12825772 — intervention group
Group type: COMPARATOR
Intervention: Odd-digit identification task
Number of subjects: 0
Study 9576383 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP plus oral polio vaccine (OPV)
Number of subjects: 711
Study 9576383 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP plus eIPV (separate injections)
Number of subjects: 711
Study 9576383 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-eIPV combined as a single injection
Number of subjects: 711
Study 9576383 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-eIPV combined, plus a separate injection of PRP-T
Number of subjects: 711
Study 9576383 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-eIPV combined and reconstituting PRP-T, as a single injection
Number of subjects: 711
Study 9576383 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of DTaP reconstituting PRP-T as a single injection
Number of subjects: 711
Study 9576383 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant PRP-T with DTaP-eIPV
Number of subjects: 711
Study 9576383 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after eIPV
Number of subjects: 711
Study 9576383 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 4 and 5 after eIPV
Number of subjects: 711
Study 8550249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle Cell Trait (SCT) carriers
Number of subjects: 13
Study 8550249 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 1978163 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms inhaled before allergen challenge
Number of subjects: 0
Study 1978163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 744812 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement during cardiovascular screening examination
Number of subjects: 8397
Study 744812 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised training techniques for observers
Number of subjects: 8397
Study 744812 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors (time of day and room temperature)
Number of subjects: 8397
Study 744812 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and overweight
Number of subjects: 8397
Study 31856741 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired kidney function (eGFR < 60 ml/min/1.73m²)
Number of subjects: 2931
Study 31856741 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly impaired kidney function (eGFR 45-<60 ml/min/1.73m²)
Number of subjects: 2931
Study 31856741 — intervention group
Group type: COMPARATOR
Intervention: No association found
Number of subjects: 2931
Study 28535809 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (0.045 mg/kg/dose) twice daily for 4 days
Number of subjects: 30
Study 28535809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25979561 — intervention group
Group type: COMPARATOR
Intervention: 500 cc Saline by rectal enema
Number of subjects: 79
Study 25979561 — intervention group
Group type: EXPERIMENTAL
Intervention: six bisacodyl tablets
Number of subjects: 79
Study 23490325 — intervention group
Group type: EXPERIMENTAL
Intervention: Epimacular brachytherapy (EMBT) with 2 mandated monthly ranibizumab injections followed by pro re nata (PRN) ranibizumab
Number of subjects: 494
Study 23490325 — intervention group
Group type: COMPARATOR
Intervention: 3 mandated monthly ranibizumab injections followed by mandated quarterly plus PRN ranibizumab
Number of subjects: 494
Study 21806770 — intervention group
Group type: EXPERIMENTAL
Intervention: Home and clinic BP monitoring
Number of subjects: 0
Study 21806770 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19333160 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 20
Study 19333160 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking by parents (FTP)
Number of subjects: 20
Study 19333160 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid (oxycodone)
Number of subjects: 20
Study 19333160 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral water)
Number of subjects: 20
Study 16937963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribose (625 mg)
Number of subjects: 11
Study 16937963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15309425 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk containing isoflavones (soy+)
Number of subjects: 89
Study 15309425 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal progesterone (TPD+)
Number of subjects: 89
Study 15309425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of soy+ and TPD+
Number of subjects: 89
Study 15309425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isoflavone-poor soymilk and progesterone-free cream)
Number of subjects: 89
Study 11412253 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy
Number of subjects: 84
Study 11412253 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparotomy
Number of subjects: 84
Study 9441144 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day catheterization
Number of subjects: 50
Study 9441144 — intervention group
Group type: COMPARATOR
Intervention: 3 days catheterization
Number of subjects: 50
Study 8221844 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial approach with 5 French preformed Judkins catheters
Number of subjects: 100
Study 8221844 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach with 6 French catheters
Number of subjects: 100
Study 8221844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 100
Study 31960907 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI (Intracytoplasmic Sperm Injection)
Number of subjects: 536
Study 31960907 — intervention group
Group type: COMPARATOR
Intervention: Mild or severe MFI
Number of subjects: 536
Study 31960907 — intervention group
Group type: COMPARATOR
Intervention: Surgical sperm extraction
Number of subjects: 536
Study 30262332 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluvia stent
Number of subjects: 465
Study 30262332 — intervention group
Group type: COMPARATOR
Intervention: Zilver PTX stent
Number of subjects: 465
Study 27942041 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterfactual thinking
Number of subjects: 84
Study 27942041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefactual thinking
Number of subjects: 84
Study 27942041 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated filler task)
Number of subjects: 84
Study 25636288 — intervention group
Group type: EXPERIMENTAL
Intervention: Rod type mandibular advancement device (MAD)
Number of subjects: 22
Study 25636288 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllable type mandibular advancement device (MAD)
Number of subjects: 22
Study 25636288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of MADs
Number of subjects: 22
Study 25636288 — intervention group
Group type: COMPARATOR
Intervention: Rod type MAD vs Controllable type MAD
Number of subjects: 22
Study 22480835 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy (LP)
Number of subjects: 74
Study 22480835 — intervention group
Group type: COMPARATOR
Intervention: Open pyloromyotomy (OP)
Number of subjects: 74
Study 20199137 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.9 mg once daily)
Number of subjects: 411
Study 20199137 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (2.5 mg/day, once or twice daily)
Number of subjects: 411
Study 18666504 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 35
Study 18666504 — intervention group
Group type: COMPARATOR
Intervention: Conventional diamond bur
Number of subjects: 35
Study 18666504 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond
Number of subjects: 35
Study 18666504 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBond FL
Number of subjects: 35
Study 18666504 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop
Number of subjects: 35
Study 18666504 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 35
Study 15639169 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-mg transdermal nicotine patch (smokers)
Number of subjects: 47
Study 15639169 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-mg transdermal nicotine patch (nonsmokers)
Number of subjects: 47
Study 15639169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonsmokers)
Number of subjects: 47
Study 15639169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (smokers)
Number of subjects: 47
Study 15639169 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (RVIP task)
Number of subjects: 47
Study 12860725 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemokine antagonist
Number of subjects: 16
Study 12860725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9884375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound thrombolysis (CUT) at 41 kHz, 18 W, for ≤6 minutes
Number of subjects: 20
Study 9275690 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 44
Study 9275690 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 9275690 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium levels in tumor tissue
Number of subjects: 44
Study 1997083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (40 ml of 0.25%)
Number of subjects: 72
Study 1997083 — intervention group
Group type: COMPARATOR
Intervention: Saline (40 ml)
Number of subjects: 72
Study 1997083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Saline
Number of subjects: 72
Study 6392105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (30 mg/kg per day for five days)
Number of subjects: 51
Study 6392105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31122212 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AAP) and Androgen Deprivation Therapy (ADT)
Number of subjects: 0
Study 31122212 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 0
Study 31122212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AAP (without ADT) and apalutamide
Number of subjects: 0
Study 29789507 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CAF) consumption (5.5 mg/kg of caffeine)
Number of subjects: 12
Study 29789507 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (DEC) consumption
Number of subjects: 12
Study 27426245 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 795
Study 27426245 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 795
Study 24981585 — intervention group
Group type: COMPARATOR
Intervention: Endovenous steam ablation (EVSA) high dose
Number of subjects: 227
Study 24981585 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 227
Study 24981585 — intervention group
Group type: COMPARATOR
Intervention: Endovenous steam ablation (EVSA)
Number of subjects: 227
Study 23108493 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance among healthy weight employees
Number of subjects: 1228
Study 23108493 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain among obese employees
Number of subjects: 1228
Study 23108493 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss among healthy weight employees
Number of subjects: 1228
Study 23108493 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants, not depressed, nonsmokers, and lower baseline absenteeism
Number of subjects: 1228
Study 19237660 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (4500 mg/d)
Number of subjects: 14
Study 19237660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17975183 — intervention group
Group type: EXPERIMENTAL
Intervention: mature-PR3-ANCA levels
Number of subjects: 156
Study 17975183 — intervention group
Group type: EXPERIMENTAL
Intervention: pro-PR3-ANCA levels
Number of subjects: 156
Study 17975183 — intervention group
Group type: EXPERIMENTAL
Intervention: PR3-ANCA levels increase
Number of subjects: 156
Study 15165408 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum LM remedy
Number of subjects: 53
Study 15165408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 12234030 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct anterior electron field treatment
Number of subjects: 266
Study 12234030 — intervention group
Group type: COMPARATOR
Intervention: Tangential photon treatment
Number of subjects: 266
Study 12234030 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 266
Study 9620901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cold dry air (CDA)
Number of subjects: 23
Study 9620901 — intervention group
Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 23
Study 7988978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime i.v. followed by Cefixime oral (2 x 2 g cefotaxime i.v. for 7 to 10 days, then 1 x 400 mg cefixime for 5 to 8 days)
Number of subjects: 100
Study 7988978 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime parenteral (2 x 2 g cefotaxime for 48 to 72 hours)
Number of subjects: 100
Study 7988978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime i.v. followed by Cefixime oral
Number of subjects: 100
Study 7988978 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime parenteral
Number of subjects: 100
Study 2590626 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) administered twice daily (Group A)
Number of subjects: 112
Study 2590626 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) administered four times a day (Group B)
Number of subjects: 112
Study 1090979 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 100
Study 1090979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31474116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter-2 inhibitor dapagliflozin
Number of subjects: 16790
Study 31474116 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16790
Study 28343676 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium abutments
Number of subjects: 12
Study 28343676 — intervention group
Group type: COMPARATOR
Intervention: Zirconia abutments
Number of subjects: 12
Study 25764916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-procedure spinal ultrasound (US) to determine the optimal lumbar level for injection
Number of subjects: 80
Study 25764916 — intervention group
Group type: COMPARATOR
Intervention: Control group determined the level of injection by palpation
Number of subjects: 80
Study 24147175 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment during pregnancy
Number of subjects: 1343
Study 24147175 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo treatment during pregnancy)
Number of subjects: 1343
Study 21868338 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA with patellar resurfacing
Number of subjects: 128
Study 21868338 — intervention group
Group type: COMPARATOR
Intervention: Control group (TKA without patellar resurfacing)
Number of subjects: 128
Study 21868338 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with varus or valgus knee
Number of subjects: 128
Study 19422464 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose levels in the second quartile (5.3-5.7 mmol L(‐1))
Number of subjects: 188
Study 19422464 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose levels in the third quartile (5.7-6.6 mmol L(‐1))
Number of subjects: 188
Study 19422464 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose levels in the fourth quartile (>= 6.6 mmol L(‐1))
Number of subjects: 188
Study 17461847 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (B-complex, C and E)
Number of subjects: 1078
Study 15026833 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-term suicidal patients
Number of subjects: 30
Study 15026833 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressed patients
Number of subjects: 30
Study 15026833 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 30
Study 11230853 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC count > 10,000
Number of subjects: 7651
Study 11230853 — intervention group
Group type: COMPARATOR
Intervention: WBC count < 10,000
Number of subjects: 7651
Study 9551672 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy (500-ml every 2 weeks until iron deficiency achieved) followed by 6-month course of alpha-interferon 2b (3 mu tiw)
Number of subjects: 38
Study 9551672 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 patients monitored for 6-8 weeks without phlebotomy)
Number of subjects: 38
Study 9551672 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy followed by interferon therapy
Number of subjects: 38
Study 9551672 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 7817727 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant mothers aged ≥ 40 years
Number of subjects: 205
Study 7817727 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with placental abruption
Number of subjects: 205
Study 7817727 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with medical treatment for essential hypertension
Number of subjects: 205
Study 7817727 — intervention group
Group type: COMPARATOR
Intervention: Post dated pregnancies estimated from first day of last menstrual period
Number of subjects: 205
Study 7817727 — intervention group
Group type: COMPARATOR
Intervention: Short symphysis-fundal height
Number of subjects: 205
Study 7817727 — intervention group
Group type: COMPARATOR
Intervention: Fetal birthweight in case pregnancies
Number of subjects: 205
Study 2646847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (1%) mixed with propofol
Number of subjects: 40
Study 2646847 — intervention group
Group type: COMPARATOR
Intervention: Glucose (5%)
Number of subjects: 40
Study 2646847 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 40
Study 9953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pethidine
Number of subjects: 8
Study 9953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diamorphine
Number of subjects: 8
Study 30240335 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 4
Study 30240335 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 4
Study 30240335 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (combined with motor imagery)
Number of subjects: 4
Study 30240335 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 4
Study 30240335 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 4
Study 30240335 — intervention group
Group type: COMPARATOR
Intervention: Control group (without stimulation)
Number of subjects: 4
Study 29465583 — intervention group
Group type: EXPERIMENTAL
Intervention: Living High-Training Low (LHTL)
Number of subjects: 35